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Cone snails  a re  tro p ica l m arin e  m ollusks th a t  enveno- 
m ate  p rey  w ith  a  com plex m ix tu re  of neu ropharm aco- 
logically  ac tive  com pounds. We re p o rt th e  d iscovery  an d  
b iochem ical c h a rac te riza tio n  of a  s tru c tu ra lly  un ique  
p ep tid e  iso la ted  from  th e  venom  of Conus m arm oreus. 
The new  pep tide , m rlOa, po ten tly  in c reased  w ith d raw al 
la tency  in  a  h o t p la te  assay  (a te s t of analgesia) a t  in ­
tra th e c a l doses th a t  do n o t p ro d u ce  m o to r im p airm en t 
as m easu red  by ro ta ro d  tes t. The sequence of m rlO a is 
NGVCCGYKLCHOC, w h ere  O is 4-fraras-hydroxyproline. 
T his sequence is h igh ly  d iverg en t from  all o th e r  know n 
conotoxins. A nalysis of a  cDNA clone encoding  th e  toxin, 
how ever, in d ica tes  th a t  i t  is  a  m em ber of th e  recen tly  
described  T-superfam ily. Total chem ical syn thesis  of th e  
th re e  possib le d isu lfide a rran g em en ts  of m rlO a w as 
achieved, an d  e lu tion  s tu d ies  in d ica te  th a t  th e  n a tiv e  
form  h as  a  d isu lfide connectiv ity  of Cysl-Cys4 an d  Cys2- 
Cys3. T his d isu lfide linkage is  u n p reced en ted  am ong 
conotoxins an d  defines a  new  fam ily of Conus pep tides.
Conus is a genus of predatory marine gastropods that en- 
venomate their prey. Prey capture is accomplished through a 
sophisticated arsenal of peptides tha t target specific ion chan­
nel and receptor subtypes. Each Conus venom appears to con­
tain a unique set of 50-200 peptides. The structure and func­
tion of only a small minority of these peptides have been 
determined to date. For peptides where function has been 
determined, three classes of targets have been elucidated: volt­
age-gated ion channels, ligand-gated ion channels, and G-pro- 
tein-linked receptors.
Conus peptides that target voltage-gated ion channels in­
clude those that delay the inactivation of sodium channels as 
well as blockers specific for sodium channels, calcium channels, 
and potassium channels. Peptides that target ligand-gated ion 
channels include antagonists of JV-methyl-D-aspartate and se­
rotonin receptors as well as competitive and non-competitive 
nicotinic receptor antagonists. Peptides that act on G protein
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receptors include neurotensin and vasopressin receptor ago­
nists. The unprecedented targeting selectivity of conotoxins 
derives from specific disulfide bond frameworks combined with 
hypervariable amino acids within disulfide loops (see Ref. 1 for 
review). Due to the high potency and exquisite selectivity of the 
conopeptides, several are in various stages of clinical develop­
ment for treatm ent of human disorders (2).
In this report we describe the isolation of a new peptide from 
the venom of the marble cone, Conus marmoreus. C. mar­
moreus is found in the Indo-Pacific, from India to the Marshall 
Islands and Fiji. It preys upon various gastropods including 
other cone snails (3). We previously reported the isolation and 
characterization of a peptide from this venom that potently 
inhibits voltage-gated sodium channels (4). In this report, we 
describe the isolation of a novel peptide that appears antinoci­
ceptive and likely represents a defining member of a new 
family of Conus peptides.
EXPERIMENTAL PROCEDURES 
Materials and HPLC1 Conditions
The venom of C. marmoreus w as obtained from snails collected in the 
Philippines. The venom was lyophilized and stored a t —70 °C until use. 
Crude venom was extracted using previously described methods (5). 
Reverse phase HPLC purification was accomplished w ith an analytical 
(4.6 mm internal d iam eter x 25 cm) Vydac Cls column. Column pore 
size was 300 A. Additional conditions are described in Fig. 1.
Reduction, Alkylation, and Peptide Sequencing
The peptide was reduced, and cysteines were carboxymethylated as 
described previously (6). The alkylated peptide was purified w ith a 
Vydac Cls analytical column using a linear gradient of 0.1% trifluoro­
acetic acid and 0.092% trifluoroacetic acid in 60% acetonitrile. Alky­
lated peptide was sequenced by Edman degradation a t the Peptide Core 
Facility a t the U niversity of U tah.
Mass Spectrometry
Electrospray ionization mass spectra were measured using a Micro­
mass Quattro II Triple Quadrupole M ass Spectrom eter with Micromass 
MassLynx operating system. The sam ples ( -100 pmol) were resus­
pended in 0.1 ml of 50%' acetonitrile with 0.05%’ trifluoroacetic acid and 
autom atically infused with a flow rate of 0.05 ml/min in the  same 
solvent system. The instrum ent was scanned over the  m/z range 50
2,000 with a capillary voltage of 2.95 kV and a cone voltage of 64 V. The 
resulting data  were analyzed using MassLynx software.
Chemical Synthesis
Peptides were synthesized, 0.45 mmol/g, on a RINK amide resin 
(Fmoc-Cys(Trityl)-Wang, Novabiochem (04-12-2050)) using Fmoc (iV-(9-
1 The abbreviations used are: HPLC, high performance liquid chro­
matography; RACE, rapid amplification of cDNAends; CAP, compound 
action potential; HFBA, heptafluorobutyric acid; GABA, ■y-aminobu- 
tyric acid.


















fluorenyl)methoxycarboxyl) chemistry and standard side chain protec­
tion except on cysteine residues. Cys residues were protected in pairs 
with either S-trityl or S-acetamidomethyl groups. Amino acid deriva­
tives were from Advanced Chemtech (Louisville, KY). All three possible 
disulfide forms of the peptide were synthesized. The peptides were 
removed from the resin and precipitated, and a two-step oxidation 
protocol was used to selectively fold the peptides as described previously 
(7).
mrlOa Precursor cDNA Cloning
The sequence of the mrlOa peptide was used to design degenerate 
oligonucleotide primers for use in 5' and 3' RACE amplification of the 
mrlOa precursor cDNA. A 3' RACE forward primer (mrlOa-F, CAG- 
GATCC AA(T/C) GGI GT(C/T/G) TG(T/C) TG(T/C) GG) was based on 
the peptide sequence NGVCCG. A 5' RACE reverse primer (mrlOa-R, 
CTGGATCC GG (A/G)TG (A/G)CA (C/A/G)A(G/A) (T/C)TT (G/A)TA 
ICC) was based on the peptide sequence GYKLCHP. C. marmoreus 
venom duct RNA was prepared, and cDNA appended with 3' and 5' 
adapter sequences was synthesized by standard methods (8). To facili­
tate cloning of the RACE amplification products, the mrlOa primers 
incorporated BamHI sites, and the 3' and 5' adapter primers contained 
XhoJ sites. RACE amplifications were performed using a “touchdown" 
cycling protocol consisting of an initial denaturation of 95 °C for 30 s 
followed by 30 cycles of 95 °C for 10 s , 65 °C for 15 s, decreasing 0.5 °C 
each cycle, 72 °C for 10 s, then 15 cycles of 95 °C for 10 s, 50 °C for 10 s, 
and 72 °C for 10 s. Polymerase chain reaction amplifications were 
performed using Taq polymerase (PE Applied Biosystems, Foster City, 
CA), and amplification reactions were analyzed by electrophoresis on 
2% agarose gels. RACE amplification products were isolated from the 
gel (Qiaex II DNA purification resin; Qiagen, Inc., Santa Clarita, CA), 
digested with BamHI and XhoJ, and cloned into the plasmid vector 
pBluescript II SK~ (Stratagene, La Jolla, CA). Plasmids containing 
inserts of the appropriate size were selected and sequenced on an ABI 
Prism 373 Fluorescent DNA Sequencer.
Experimental A nim als
Adult male CF-1 mice (25-35 g) were used for all experiments. Mice 
were housed five per cage, maintained on a 12-h light/dark cycle, and 
allowed free access to food and water.
Hot Plate Test
Analgesic activity was assessed by placing mice in a plexiglass cyl­
inder (10.2-cm diameter x 30.5 cm high) on a hot plate (Mirak model 
HP72935, Barnstead/Thermolyne, Dubuque, IA) maintained at 55 °C. 
Thirty minutes before the hot plate test, animals were treated with a 
dose of mrlOa or vehicle (0.9% saline) by free-hand intrathecal injection 
(9) in a volume of 5 /ul. The time from being placed on the plate until 
each mouse either licked its hind paws or jumped was recorded with a 
stopwatch by a trained observer unaware of the treatments. An arbi­
trary cut-off time of 60 s was adopted to minimize tissue injury. Hot 
plate test data were analyzed by analysis of variance followed by Dun- 
nett’s test for multiple comparison, with p < 0.05 considered significant. 
Statistical analysis was performed with GraphPad Prism software 
(San Diego, CA). Shortly after the hot plate test, mice were placed on a
3-cm-diameter rotarod turning at 6 rpm (model 7650, Ugo Basile, 
Comerio, Italy). Mice were considered impaired if they fell three times 
in 1 min.
Electrophysiological Assays
liana pipiens, 2.5 to 3 inches long, were used. The dissected prepa­
ration consisted of the 9th and 10th spinal nerves and their continua­
tion down the sciatic nerve to the posterior crural nerve, freed from the 
skin that it innervates (see e.g. Ref. 10). Each spinal nerve was severed 
from the spine several millimeters proximal to its sympathetic ramus 
such that it could be electrically stimulated without activating sympa­
thetic axons (see e.g. Ref. 11).
For extracellular stimulation and recording, the preparation was 
placed in a chamber fabricated from the silicone elastomer Sylgard 
(Dow Corning). The chamber was essentially a series of wells, each 
separated from its closest neighbor by about 1 mm. The proximal ends 
of the 9th and 10th nerves were placed in separate wells; the sciatic 
portion lay in a third well, whereas the attached lateral crural nerve 
spanned two additional wells, each 4 mm in diameter. All wells were 
filled with frog Ringer’s solution (111 mM NaCl, 2 mM KCl, 1.8 mM 
CaCl2, 10 mM Na-HEPES (pH 7.2)). All portions of the nerve that 
draped over the partitions between wells and otherwise exposed to air 
were covered with Vaseline. One of a pair of stainless steel wire stim­
ulating electrodes was placed in the well on either side of the Vaseline 
gap covering a spinal nerve. One of a pair of stainless steel wire 
recording electrodes was placed in the well on either side of the Vaseline 
gap covering the lateral crural nerve. Thus for both stimulation and 
recording, one electrode was in the same well that containing a cut end 
of the nerve, whereas its counterpart was in the well containing the 
portion of the nerve just distal (stimulation) or proximal (recording) to 
the cut end. The stimulating electrodes led to a Grass SIU5 stimulus 
isolation unit connected to a Grass S-88 stimulator. The recording 
electrode in the most distal well, containing the cut end of the posterior 
crural nerve, led to the positive input of a Grass P-55 differential 
preamplifier, whereas its counterpart, led to the negative input. Re­
cordings were made with a preamplifier gain of 1000, RC-filtered (1 Hz 
alternating current and 1 kHz low pass) and digitized at a sampling 
rate of 4 kHz with a National Instruments Lab-NB board in a Macin­
tosh Quadra 840 computer. Homemade virtual instruments (National 
Instruments LabVIEW) were used for data acquisition and analysis.
Supramaximal stimuli (1 ms, -30 V) were applied to a spinal nerve 
once a minute while recording propagated compound action potentials 
(CAPs) reaching the other end of the preparation. Conopeptide was 
introduced into the well just proximal to that containing the distal cut 
end of the posterior crural nerve.
Oocyte Assays
Xenopus oocytes were injected with cRNA encoding human nAChR 
subunits as described previously (12, 13). Oocytes injected with a4j32 
subunits were placed in a recording chamber ( -30 /ul), voltage-clamped, 
and assessed for expression of receptor using a 1-s pulse of 300 /am 
acetylcholine (see Lu et al. (14) for details). Peptide was then added to 
the bath to achieve a final concentration of 10 /am.
Receptor B inding  Assays
a-Conotoxin GVIA Binding—w-Conotoxin GVIA was iodinated by 
previously described methods (15). The binding protocol was a modifi­
cation of that described in Hillyard et al. (16). Crude brain membranes 
from Harlan Sprague-Dawley rats were prepared as described by 
Catterall (17), with modifications in buffer components as described in 
Cruz and Olivera (15). The binding of 12i’I-labeled w-conotoxin GVIA to 
rat brain membrane was measured in a 200-/J assay mix that contained 
approximately 10 /ng of membrane protein, 100,000 cpm of carrier-free 
ft>-r12i’IJconotoxin GVIA (approximately 150 pm), 0.2 mg/ml lysozyme, 
0.32 M sucrose, 100 mM NaCl, and 5 mM HEPES/Tris (pH 7.4). Nonspe­
cific binding was measured by preincubating the membrane prepara­
tion with 1 /am unlabeled w-conotoxin GVIA for 30 min on ice before the 
addition of rx-| l:';i 11 conotoxin GVIA. mrlOa was assessed for activity by 
preincubating the toxin for 30 min on ice. The final assay mix was then 
incubated at room temperature for 30 min and diluted with 1.5 ml of 
wash buffer containing 160 mM NaCl, 1.5 mM CaCl2, 2 mg/ml bovine 
serum albumin, 5 mM HEPES/Tris (pH 7.4). Membranes were collected 
on glass fiber filters (Whatman GF/C soaked in 0.1% polyethyleneam- 
ine) using a Brandell apparatus model M-24 and washed with 1.5 ml of 
wash buffer four times. The amount of radioactivity in the filters was 
then measured.
a)f}2 Nicotinic Acetylcholme Receptor Binding—The procedure of 
Pabreza et al. (18) was used. p’HJCytisine (15-40 Ci/mmol) was from 
PerkinElmer Life Sciences. Rat forebrain membrane was incubated for 
75 min at 4 °C in 50 mM Tris-HCl (pH 7.0 at room temperature) 
containing 120 mM NaCl, 5 mM KCl, 1 mM MgCl2, and 2.5 mM CaCl2. 
Nonspecific binding was defined with 10 /am nicotine.
The remaining assays were carried out under contract with Nova- 
screen (Hanover, Maryland). The essentials of the procedures used are 
summarized below.
Adrenergic a l Binding Assay—Rat forebrain membranes were incu­
bated with 0.3 nM p’HJprazosin (70-87 Ci/mmol). Reactions were car­
ried out in 50 mM Tris-HCl (pH 7.7) at 25 °C for 60 min. Prazosin (1.0 
/am) was used to define nonspecific binding (19, 20).
Adrenergic a2 Binding Assay—Rat cortical membranes were incu­
bated with 1.0 nM [3HJRX821002 (40-67 Ci/mmol). Reactions were 
carried out in 50 mM Tris-HCl (pH 7.4) at 25 °C for 75 min. RX821002 
(0.1 /am) was used to define nonspecific binding (20, 2 1).
Adrenergic fil Binding Assay—Rat cortical membranes were incu­
bated with 0.2 nM (- )[125IJiodopindolol (2200 Ci/mmol) and 120 nM 
ICI-118,551 (to block adrenergic (32 receptors). Reactions were carried 
out in 50 mM Tris-HCl (pH 7.5) containing 150 mM NaCl, 2.5 mM MgCl2, 
and 0.5 mM ascorbate at 37 °C for 60 min. Alprenolol HC1 (10 /am) was 
used to define nonspecific binding (22, 23).

















were incubated with 5.0 nM PHJGABA (70-90 Ci/niniol). Reactions 
were carried out in 50 niM Tris-HCl (pH 7.4) at 0 —4°C for 60 min. 
GABA (1.0 jliM) was used to define nonspecific binding (24, 25).
Glutamate, A?-Afe/ry/-D-aspartate Agonist Site Binding Assay—Rat 
forebrain membranes were incubated with 2.0 nM pHfCGP 39653 
(25-60 Ci/mmol). Reactions were carried out in 50 mM Tris-HCl (pH 
7.4) at 0 -4  °C for 60 min. iV-Methyl-D-aspartate (1.0 mM) was used to 
define nonspecific binding (26, 27).
Glycine, Strychnine-sensitive Binding Assay—Rat spinal cord mem­
branes were incubated with 16.0 nM f’HJstrychnine (15—40 Ci/mmol). 
Reactions were carried out in 50 mM Na2H P04 and 50 mM KH2P 0 4 (pH 
7.1) containing 200 mM NaCl a t 0—4 °C for 60 min. Strychnine nitrate 
(1.0 mM) was used to define nonspecific binding (28, 29).
Histamine H , Binding Assay—Bovine cerebellar membranes were 
incubated with 2.0 nM pHJpyrilamine (15—25 Ci/mmol). Reactions were 
carried out in 50 mM Tris-HCl (pH 7.5) at 25 °C for 60 min. Triprolidine 
(10 jiiM) was used to define nonspecific binding (30-32).
Muscarinic Central Binding Assay—Rat cortical membranes were 
incubated with 0.15 nM pHJquinuclidinylbenzilate (30—60 Ci/mmol). 
Reactions were carried out in 50 mM Tris-HCl (pH 7.4) at 25 °C for 75 
min. Atropine (0.1 jiim) was used to define nonspecific binding (33-35).
Neurotensin Binding Assay—Rat forebrain membranes were incu­
bated with 2.0 nM pHJneurotensin (70—120 Ci/mmol). Reactions were 
carried out in 50 mM Tris-HCl (pH 7.4) containing 0.04% bacitracin, 
0.1% bovine serum albumin, and 1 mM Na2EDTA at 25 °C for 60 min. 
Neurotensin (1.0 jiim) was used to define nonspecific binding (36, 37).
Opiate SI Binding Assay—Rat forebrain membranes were incubated 
with 1.0 nM pHJdeltorphin 11 (30—60 Ci/mmol). Reactions were carried 
out in 50 mM Tris-HCl (pH 7.4) at 25 °C for 90 min. fu-Pen2, D-Pen5J- 
enkephalin (1.0 jiim) was used to define nonspecific binding (38, 39).
Opiate k 1 Binding Assay—Guinea pig cerebellar membranes were 
incubated with 0.75 nM pHJU-69593 (40-60 Ci/mmol). Reactions were 
carried out in 50 mM HEPES (pH 7.4) at 30 °C for 120 min. U-69593 (1.0 
jlim) was used to define nonspecific binding (40 —42).
Opiate p. Binding Assay—Rat forebrain membranes were incubated 
with 1.0 nM pHJTyr-D-Ala-Gly-iV-methyl-Phe-Gly-ol (DAMGO) (30-60 
Ci/mmol). Reactions were carried out in 50 mM Tris-HCl (pH 7.4) at 
25 °C for 90 min. Naloxone (1.0 ;nM) was used to define nonspecific 
binding (43, 44).
Norepinephrine Transporter Binding Assay—Rat forebrain mem­
branes were incubated with 1.0 nM pHJnisoxetine (60—85 Ci/mmol). 
Reactions were carried out in 50 mM Tris-HCl (pH 7.4) containing 300 
mM NaCl and 5 mM KCl a t 0—4 °C for 4 h. Desipramine (1.0 jim) was 
used to define nonspecific binding (45, 46).
Serotonin 5HT:, Binding Assay—N1E-115 cells were incubated with 
0.35 nM PHJGR65630 (30—70 Ci/mmol). Reactions were carried out in 
20 mM HEPES (pH 7.4) containing 150 mM NaCl a t 25 °C for 60 min. 
MDL-72222 (1.0 jiim) was used to define nonspecific binding (47-49).
Serotonin Transporter Binding Assay—Rat forebrain membranes 
were incubated with 0.7 nM pHJcitalopram (70—87 Ci/mmol). Reactions 
were carried out in 50 mM Tris-HCl (pH 7.4) containing 120 mM NaCl 
and 5 mM KCl at 25 °C for 60 min. Imipramine (10 jim) was used to 
define nonspecific binding (50, 51).
Dopamine Transporter Binding Assay—Guinea pig striatal mem­
branes were incubated with 12.0 jim PHJW1N,35,428 (60—87 Ci/mmol). 
Reactions were carried out in 50 mM Tris-HCl (pH 7.4) containing 120 
niM NaCl at 0 -4  °C for 2 h. GBR-12909 (0.1 jiim) was used to define 
nonspecific binding (52, 53).
RESULTS
Purification and Sequencing o f mrlOa—Extracted crude 
venom from C. marmoreus was initially size-fractionated using 
a Sephadex G-25 column (see Fig. 1). Column fractions eluting 
in a range corresponding to small peptides were further puri­
fied using reverse phase HPLC utilizing conditions described 
under “Methods and Methods” and in Fig. 1. Throughout sub­
sequent purification, HPLC fractions were assayed by means of 
intracerebral ventricular injection into mice (54). Intracerebral 
ventricular injection of fractions containing mrlOa produced 
hypokinetic “sluggish” symptoms. The venom fraction was ini­
tially purified using a trifluoroacetic/acetonitrile gradient sys­
tem. To obtain further purification, the new fractions were 
lyophilized and resuspended in 0.05% heptafluorobutyric acid 
(HFBA) and run on a reverse phase C18 column using a 0.05% 
HFBA, acetonitrile gradient. Further purification was obtained
Fig. 1. P u rifica tio n  of mrlOa. A, crude venom extract was size- 
fractionated using a column (2.54-cm diameter x  188-cm length) 
packed with Sephadex G-25 (dry bead diameter 20-80 jum). Elution 
buffer was 1.1% acetic acid at 4 °C. Flow rate was —18.3 ml/h. B, 
fractions from the indicated area in panel A  (bracket) were combined, 
lyophilized, and resuspended in 0.1% trifluoroacetic acid and purified 
on a Vydak C-18 column (see “Experimental Procedures”) using a linear 
1% buffer B/min gradient where buffer A is 0.1% trifluoroacetic acid and 
buffer B is 0.092% trifluoroacetic acid, 60% acetonitrile. The gradient 
began at 10% buffer B. C, the material indicated in panel B (arrow) was 
lyophilized and resuspended in 0.05% heptafluorobutyric acid. It was 
then purified on a Vydac C-18 column using a linear 1% buffer B/min 
gradient where buffer A is 0.05% HFBA and buffer B is 0.05% HFBA, 
60% acetonitrile. The gradient began at 30% buffer B. D, the material 
indicated in panel C (arrow) was lyophilized and dissolved in 10 mM 
NaH2P 0 4, 50% CH,CN (pH 2.5) (buffer A). The material was then 
purified using a Vydac protein-SCX (strong cation exchange) column 
(0.75 x 5 cm) using a linear 1% B/min gradient where buffer B is the 
same as buffer A but with the addition of 250 mM NaCl. The flow rate 
was 1 ml/min in panels B, C, and D, Absorbance was monitored a t 233, 
214, 214, and 220 nm in panels A, B, C, and D, respectively.
using strong cation exchange chromatography. The fraction 
was then desalted using reverse phase HPLC. Final purified 
product is shown in Fig. 2, panel B.
The disulfide bonds of the purified peptide were reduced, and 
Cys residues were carboxymethylated. The alkylated peptide 
was then chemically sequenced and yielded NGVC- 
CGYKLCHOC, where O is 4-iraras-hydroxyproline. Mass spec­
trometry of the peptide verified the sequence and indicated 
that Cys residues are present as disulfides and the C terminus 
is the free carboxyl (monoisotopic MH+ (Da): calculated, 
1408.5; observed, 1408.5).
Peptide Synthesis—The sequence of the peptide was inde­
pendently confirmed by preparation of synthetic peptide as 
described under “Experimental Procedures.” The mrlOa pep­
tide has four Cys residues and, therefore, three possible disul­
fide linkages. All three disulfide bond linkages were synthe­
sized to unequivocally identify the native configuration. 
Peptides were initially synthesized in linear form using pair­
wise protection of Cys residues (see “Experimental Proce­














































80 90 100 110 120 
CAACAGGCAGA ATG CGC TGT CTC CCA GTC TTG ATC ATT CTT CTG CTG CTG ACTM R C L P V L I I L L L L T> 
signal sequence
130 140 150 160 170 
GCA TCT GCA CCT GGC GTT GTT GTC CTA CCG AAG ACC GAA GAT GAT GTG CCC
220 processing
ATG TCA TCT GTC TAC GGT AAT GGA AAG AGT ATC CTA CGA GGA ATT CTG AGG
Time (min)
Fig. 2. E lu tion  s tud ies  of mrlOa. A, -200 pmol each of the three 
possible disulfide forms of synthetic mrlOa were chromatographed us­
ing reverse phase HPLC. The disulfide connectivities are: 1, Cvsl-Cvs3. 
Cys2-Cys4; 2, Cysl-Cys4. Cys2-Cys3; 3. Cysl-Cys2. Cys3-Cys4. B~  100 
pmol of native mrlOa. C, -200 pmol each of synthetic Cysl-Cys3. 
Cys2-Cys4 and native mrlOa. £>. -200 pmol each of synthetic Cysl- 
Cys4, Cys2-Cys3 and native mrlOa. Note that the two materials co­
elute. E, -200 pmol each of synthetic Cysl-Cys2, Cys3-Cys4 and native 
mrlOa. In all HPLC runs, buffer A = 0.1% trifluoroacetic acid, and 
buffer B = 0.092% trifluoroacetic acid. 60% acetonitrile. The gradient 
began a t 15% B and increased 1% B/min. The column was an analytical 
C-18 (see “Experimental Procedures"). The flow rate was 1 ml/min. 
Absorbance was monitored a t 220 nm.
groups, and ferricyanide oxidation was used to close the first 
disulfide bridge. Iodine oxidation was subsequently used to 
remove S-acetamidomethyl protection groups and close the 
second bridge. Using this method, each possible disulfide a r ­
rangem ent was synthesized, i.e. Cysl-Cys2, Cys3-Cys4; Cysl- 
Cys3, Cys2-Cys4, and Cysl-Cys4, Cys2-Cys3. Final purified 
yields of each peptide were 12.5, 5.2, and 12.4%, respectively. 
Synthesis of each isomer was confirmed w ith m ass spectrome­
try  (calculated monoisotopic MH+, 1408.5; observed, 1408.6, 
1408.7, and 1408.6, respectively). The three forms of the pep­
tide were distinguishable using reverse phase HPLC based on 
elution time. In addition, they were distinguishable by peak 
width, w ith the (Cysl-Cys4, Cys2-Cys3) form having the n a r­
rowest peak w idth (Fig. 2). Both the elution tim e and peak 
shape of the (Cysl-Cys4, Cys2-Cys3) disulfide form m atch th a t 
of the native peptide. Additionally, co-injection of each syn­
thetic form indicates th a t native m rlO a co-elutes only with
230 240 250 260 270 280AAC GGT GTT TGC TGT GGC TAT AAG TTG TGC CAT CCA TGT TAA CCAGCATGAAGGGA 
N G V C C G Y K L C H P C  *> 
mature mrlOa conotoxin
290 300 310 320 330 340 350AATGACTTTGGATGAGACCCCTGCGAACTGTCCCTGGATGTGAAATTTGGAAAGCAGACTGTTCCTTTCG
360 370 380 390 400 410 420
CACGTATT CGTGGAATTTCGAATGGTCGTAAACAACACGCTGCCACTTGCAGGCTACTATCTCTCTGTCC
430 440 450 460 470 480 490TTTCATCTGTGGAAATGGATGATCTAACAACTGAAATATCAGAAATTTTTCAATGGCTATACACTATGAC
500 510 520 530 540 550 560
CATGTAGTCAGTAATTATATCATTTGGACCTTTTGAAATATTTTTCAATATGTAAAGTTTTTGCACCCTG
570 580 590 600 610 .620 630GAAAGGTCTTTTGGAGTTAAATATTTTAGTATGTTATGTTTTGCATACAAGTTATAGAATGCTGTCTTTC
640 650 660 670 680 690 700TTTTTGTTCCCACATCAATGGTGGGGGCAGAAATTATTTGTTTTGGTCAATGTAATTATGACCTGCATTT
710 720 730 740 750 760 770AGTGCTATAGTGATTGCATTTTCAGCGTGGAATGTTTAATCTGCAAACAGAAAGTGGTTGATCGACTAAT
poly A site780 790 800AAAGATTTGCATGGCACAAAAAAAAAAAAAAAAA
Fig. 3. The M rlO .l cDNA and  encoded p ro te in  a re  show n. The
signal sequence and mature toxin regions are underlined. The putative 
proteolytic processing site ill) is indicated.
synthetic peptide of the (Cysl-Cys4, Cys2-Cys3) configuration, 
providing unam biguous evidence for th is disulfide linkage be­
ing native (Fig. 2).
mrlOa Precursor Structure—The m rlO a peptide sequence 
was used to design degenerate polymerase chain reaction prim ­
ers for 3' and 5 ' RACE (rapid amplification of cDNA ends) 
amplification of the complete m rlO a precursor cDNA. The po­
lymerase chain reaction prim ers were designed to yield over­
lapping 3 ' and 5 ' RACE products, allowing the complete cDNA 
sequence to be assembled from the two sequences. Amplifica­
tion of C. marmoreus cDNA gave specific products of 610 base 
pairs in the 3' RACE and 300 base pairs in the 5 ' RACE 
reactions. These polymerase chain reaction products were 
cloned, and m ultiple clones of both the 5 ' and 3 ' RACE products 
were isolated and sequenced. For both the 5 ' and 3' RACE 
products, the m ultiple clones all represented the same se­
quence, and the appropriate segments of the m rlO a peptide 
sequence were represented by the cloned sequence. The 5' and 
3 ' RACE product sequences were assembled to give the com­
plete m rlOa prepropeptide precursor cDNA sequence (Fig. 3). 
The first ATG s ta r t codon encountered from the 5' end of the 
cDNA initiates an open reading fram e of 61 amino acids, en ­
coding a protein w ith a structure typical of a conotoxin pre­
propeptide. The first 24 N-term inal amino acids compose a 
hydrophobic signal sequence region. The m ature m rlO a pep­
tide sequence is located a t the C-term inal end of the precursor 
sequence, im m ediately preceded by a basic amino acid (Arg) 
signaling proteolytic peptide processing. The stop codon is im ­
mediately downstream of the last cysteine residue of the mrlOa 
peptide. A 3 '-un translated  region of —500 base pairs is term i­
nated  by a typical poly(A)+ addition signal (AATAAA) and a 
poly(A) tail.
The m rlO a precursor exhibits significant sequence homology 
to a previously identified family of conotoxin genes, the T- 
superfamily, although the m ature m rlO a peptide is distinct 
from any of the previously isolated T-superfamily conotoxins 
(Fig. 4). Previously isolated T-superfamily conotoxins all share 
the cysteine framework CC^CC (7). The cysteine framework of 
the m rlO a conotoxin is sim ilar to th a t of the a-conotoxins, a 
large family of nicotinic receptor antagonists, yet the sequence 
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Fig. 4. The m rlO a p rep ro p ep tid e  sequence is show n aligned  w ith  rep resen ta tiv e  m em bers of th e  T-superfam ily of eonotoxins 
(Gm5.1, Gm5.2, Im5.1, Tx5.1), along w ith  tw o exam ples of a-conotoxin p recu rso rs  (a-SI, a-GI). The mrlOa precursor has substantial 
sequence homology with T-superfamily precursor sequences, although the mature peptide has a distinct cysteine pattern, and there is little amino 
acid similarity. Although the mrlOa conotoxin has a cysteine pattern similar to th a t of a-conotoxins, the mrlOa precursor is unrelated to the 










and a-conotoxins are derived from completely unrelated pre­
cursors (Fig. 4). The occurrence of the mrlOa conotoxin within 
the T-superfamily provides a demonstration of the ability of 
Conus species to evolve novel toxin peptide frameworks within 
the same conotoxin superfamily.
Biological Activity—The biological activity of many Conus 
peptides can be grouped into three major categories: those that 
produce excitotoxic shock, those that produce paralysis, and 
those that inhibit sensory circuits. Intraperitoneal injection of 
30 nmol of mrlOa into three mice produced neither neuromus­
cular excitation nor muscle paralysis. We next tested the pep­
tide for analgesic activity using mice in a hot plate assay. 
Native peptide (2 nmol) injected intrathecally into three mice 
produced a latency to first hind paw lick (a nociceptive re­
sponse) of 39.5 ± 13.5 s, suggestive of potent analgesic activity. 
Due to a limited quantity of native material, a complete dose- 
response study could not be performed, and all further tests 
were performed with synthetic peptide.
Intrathecal administration of synthetic mrlOa produced a 
dose-dependent (0.1-10 nmol) increase in the latency to first 
hind paw lick (F(3,15) = 7.5, p  <  0.01) in the hot plate test. At 
doses of 1 and 10 nmol, mrlOa significantly increased the 
latency to lick the hind paw in this test (Fig. 5).
Motor impairment was assessed in all injected mice by 
means of a rotarod test (see “Experimental Procedures”). Motor 
impairment was not seen in any mouse injected either in tra­
thecally or intraperitoneally. Injection of high doses of mrlOa 
(25 nmol) by intracerebral ventricular administration resulted 
in akinesia and seizures in two mice tested. Further testing by 
intracerebral ventricular administration was not performed.
Molecular Target—mrlOa was tested in a number of electro­
physiological and binding assays (see “Experimental Proce­
dures”) in an effort to define its molecular target. To test effects 
on N a " channels, we used a frog peripheral nerve preparation 
containing sensory fibers. mrlOa (100 /am) produced no appre­
ciable effects on CAPs recorded from the posterior crural nerve, 
which innervates the skin (Fig. 6). Clearly evident in the traces 
are fast-conducting Act- and Aj3-CAPs as well as much slower 
conducting C-CAPs. The A-CAPs and C-CAPs in the posterior 
crural nerve are tetrodotoxin-sensitive and tetrodotoxin-resis- 
tant, respectively,2 just like those seen in the frog sciatic nerve 
(cf. Refs. 55 and 56). It is notable that many, but not all, of the 
CAPs in the posterior crural nerve are sensitive to other cono­
toxins known to affect action potentials,3 for example fi-cono- 
toxin PVIA, which targets N a " channels (57), and xA-conotoxin 
SIVA, which targets K" channels (58). mrlOa also was without 
effect on nicotinic acetylcholine receptors, the site of action of 
a-conotoxins. Ten /am mrlOa does not activate a4|32 nicotinic 
acetylcholine receptors expressed in Xenopus oocytes, nor does 
it compete for [3H] cytisine binding to putative a4|32 receptors 
in ra t brain membranes.
■ D. Yoshikami, unpublished information.
’ S. D. Abbaszadeh and D. Yoshikami, unpublished information.
Fig. 5. m rlO a p roduces dose-dependent analgesia  in  th e  h o t 
p la te  test. Male CF-1 mice were injected intrathecally (i.t.) with either 
vehicle (0.9% saline) or mrlOa. Thirty minutes later mice were placed 
on the hot plate and latency to first hind paw lick was recorded. Each 
bar shows the mean ± S.E. of 3—6 mice per group; *, p < 0.05, and **, 
p < 0.01 versus vehicle-treated control group.
Fig. 6. m rlO a does n o t affect CAPs in  th e  p o ste rio r c ru ra l 
nerve in n e rv a tin g  skin. Control response (lower trace) and tha t fol­
lowing 17-min exposure to 100 /lim mrlOa (upper trace) are very similar, 
and small differences in amplitudes of the CAPs in these two traces are 
likely due to fluid evaporation at the Vaseline gap across which the 
CAPs were recorded. Resolution of fast Act- and A^-CAPs (first two 
major peaks) in the same sweep tha t displays C-CAPs (multi-peaked 
waveform at f > 100 ms) is achieved by use of a logarithmic time base 
(cf. Ref. 66). Time-axis units are ms, and traces are displaced from each 
other by 1.5 mV. Stimulus (duration 1 ms) was applied at: t 20 ms, 
resulting in the artifact seen as the initial small deflection (see arrow) 
preceding the large twin A-CAP peaks.
mrlO also failed to compete for binding to many other recep­
tor targets associated with analgesia including iV-type calcium 
channels (the binding site of w-conotoxins GVIA and MVIIA), 
neurotensin receptors (the molecular target of contulakin-G), 
a l , a2, or J31 adrenergic receptors, GABAa , glycine or hista­
mine 1, central muscarine, S1-, k1 -, or /i-opiate receptors, or 
5HT3 receptors and did not compete for binding to norepineph­
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We describe the characterization of a novel peptide with 
apparent potent antinociceptive activity isolated from the 
venom of the mollusk-hunting species, C. marmoreus. Like 
many Conus peptides, mrlOa is rich in disulfides, with 4 of 13 
residues being Cys residues. Two other groups of Conus pep­
tides were previously shown to have four Cys residues, the 
a-conotoxins (59) and T-superfamily conotoxins (7). All a-cono­
toxins and T-superfamily conotoxins characterized to date (1, 7, 
60) have Cysl-Cys3, Cys2-Cys4 connectivity. In contrast, 
mrlOa has Cysl-Cys4, Cys2-Cys3 connectivity, a pattern un­
precedented among Conus peptides. In addition to the novel 
disulfide bond connectivity, mrlOa bears little if any sequence 
similarity to the a-conotoxins or other T-superfamily peptides, 
and clearly represents a new class of Conus peptide (Table I).
Conus peptides are initially translated from mRNA as pre­
propeptide precursors that are subsequently processed into the 
small mature neuroactive toxins. Conopeptides can be grouped 
into superfamilies based on the signal sequences of the precur­
sors and on the disulfide framework of the mature toxin. Thus, 
in the O-superfamily for example there are u>-conotoxins (Ca2+ 
channel antagonists), juO-conotoxins (Na+ channel blockers), 
S-conotoxins (peptides that delay inactivation of Na^ chan­
nels), and x-conotoxins (K^ channel blockers). Peptides in 
these four families share a highly conserved signal sequence as 
well as the same disulfide framework. Thus, the polypeptides 
belonging to the same superfamily can be processed to mature 
conotoxins that are biochemically and pharmacologically 
diverse.
The mrlOa peptide described in this report provides a new 
twist to this paradigm. Analysis of a cDNA clone of mrlOa 
clearly indicated that this peptide is a member of the T-super- 
family. In members of the O-superfamily, although there is 
hypermutation of toxin sequences, the disulfide connectivity is 
conserved. In contrast, the previously identified T-superfamily
conotoxins versus mrlOa have both a divergent arrangement of 
Cys residues and, most surprisingly, a different disulfide bond 
linkage. This is the first known example of such a divergent 
disulfide connectivity within members of a Conus peptide su­
perfamily. Thus, the mrlOA peptide defines a distinct branch of 
the T-conopeptide superfamily clearly different from T-super- 
family peptides previously characterized. It seems likely that 
more than one pharmacological family of Conus peptides will 
compose each branch.
Although the purpose for which C. marmoreus employs 
mrlOa is unknown, it is possible that this is an example of a 
peptide tha t inhibits specific neuronal circuits in prey. We 
demonstrate in this report that mrlOa produces inhibition of 
withdrawal response when tested in a mouse hot plate assay at 
intrathecal doses that do not produce gross motor impairment 
or impair performance on the rotarod test. We have postulated 
elsewhere that a “nirvana cabal” of peptides is used to inhibit 
sensory circuitry of the fish prey of piscivorous Conus species 
that use a net strategy (61); the discovery of the mrlOa peptide 
raises the possibility that the mollusk-hunting C. marmoreus 
uses a similar nirvana cabal strategy.
Due to the potency and selectivity of Conus peptides, several 
are now in various stages of clinical trials. Two Conus peptides 
are being developed for the treatm ent of pain. The most ad­
vanced is u)-conotoxin MVIIA (ziconotide), an JV-type calcium 
channel blocker (62). u>-Conotoxin MVIIA, isolated from Conus 
magus, is approximately 1000 times more potent than mor­
phine, yet does not produce the tolerance or addictive proper­
ties of opiates. u>-Conotoxin MVIIA has completed Phase III 
clinical trials in humans and now awaits FDA approval as a 
new therapeutic agent. u>-Conotoxin MVIIA is introduced into 
human patients by means of an implantable, programmable 
pump with a catheter threaded into the intrathecal space. 
Preclinical testing is being carried out on another Conus pep­
tide, contulakin-G, isolated from Conus geographus (63); con- 
tulakin is an agonist of neurotensin receptors but, interest­
ingly, appears significantly more potent than neurotensin in 
inhibiting pain in in vivo assays. Contulakin-G is being in­
vestigated for use in post-surgical pain. For a review of cono­
toxins and therapeutic applications, see Jones and Bulaj (2) 
and Adams et al. (65). The mechanism of action of mrlOa is 
unknown, but results of the present study indicate th a t its 
mechanism is distinct from a-, u>-, S-, or xA-conotoxins as well 
as contulakin-G. In addition, it fails to act a t numerous other 
receptor sites associated with analgesia.
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